Optometry and Vision Science Program, Faculty of Health Sciences, University Kebangsaan Malaysia, Kuala Lumpur 50300, Malaysia.
Department of Optometry, Supreme Institute of Management and Technology, Mankundu Hooghly, West Bengal 712123, India.
Int J Environ Res Public Health. 2020 Sep 2;17(17):6378. doi: 10.3390/ijerph17176378.
Polypoidal choroidal vasculopathy (PCV), a subtype of neovascular age-related macular degeneration, requires repeated treatment. The objective of this pilot study was to evaluate and compare vision-targeted quality of life (QOL) at baseline and after 6 months of treatment in patients with PCV. Naive PCV patients were recruited. Visual functions assessed were distance visual acuity (DVA), near visual acuity (NVA), contrast sensitivity (CS), reading speed (RS), and QOL at baseline and after 6 months of treatment. Thirty patients (average age of 67.62 ± 8.05 years) revealed mean DVA and NVA improvements of 0.24 logMAR and 0.30 logMAR, respectively. Mean CS and RS improved by 0.39 log contrast and 25.58 words per minute, respectively. The National Eye Institute Visual Function Questionnaire 25 (NEI-VFQ-25) composite score significantly increased from a baseline of 66.73 ± 13.74 to 73.54 ± 14.26. Twenty-eight of the patients showed overall improvement in QOL score by 5 units or more or remained stable. Subscales of NEI-VFQ-25 significantly improved, with general vision, mental health, and role difficulties improving by 10 or more units. The present pilot study reports a significant improvement of QOL in PCV patients after 6 months of treatment, with mental health, role difficulties, social functioning, and distance vision activities being the most improved subscales.
息肉状脉络膜血管病变（PCV），一种新生血管性年龄相关性黄斑变性的亚型，需要反复治疗。本初步研究的目的是评估和比较初诊为 PCV 的患者在基线时和治疗 6 个月后的视力相关生活质量（QOL）。纳入未经治疗的 PCV 患者。评估的视觉功能包括远视力（DVA）、近视力（NVA）、对比敏感度（CS）、阅读速度（RS）和基线及治疗 6 个月后的 QOL。30 名患者（平均年龄 67.62±8.05 岁）的 DVA 和 NVA 分别平均提高了 0.24 logMAR 和 0.30 logMAR。CS 和 RS 分别平均提高了 0.39 对数对比度和 25.58 个单词/分钟。国家眼科研究所视觉功能问卷 25 项（NEI-VFQ-25）综合评分从基线的 66.73±13.74 显著提高到 73.54±14.26。28 名患者的 QOL 评分总体提高了 5 个单位或更多，或保持稳定。NEI-VFQ-25 的子量表显著改善，总体视力、心理健康和角色困难改善了 10 个单位或更多。本初步研究报告了 PCV 患者在治疗 6 个月后 QOL 显著改善，心理健康、角色困难、社会功能和远距视力活动改善最明显。
